OTX008

· Oncoethix GmbH, a subsidiary of Merck & Co.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OTX008, covering 2012-11-09 to 2012-11-09. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors [Phase 1]

See pricing